Exosome Market Report [358 Pages]
Product Launches on Monday, April 12, 2021 –
Pre-Order Now for 10% Off
Exosomes are extracellular vesicles (EVs) of endosomal origin that range in size between 30 and 100 nanometers. Exosomes are secreted by a wide range of cells and the contents carried by them depend strongly on their cell of origin. Virtually all living cells utilize exosome-mediated communication. Exosomes carry cell-specific cargos of proteins, lipids, and nucleic acids that are selectively taken up by recipient cells.
As the exosomes are secreted by a diverse range of living cell types, their cargos are different from each other. Thus, the cargo can offer prognostic information for range of diseases, including cardiovascular, renal, neurodegenerative, and metabolic diseases, as well as cancer. Researchers investigating exosome biomarkers have discovered, identified, and reported the presence of hundreds of biomolecules in the lumen of exosomes. This discovery has compelled a rapid rise in exosome-related cancer biomarker research, including the use of exosomes for the detection, monitoring, and treatment of a diverse range of oncologic conditions.
The major reason for the focus on the use of exosomes as biomarkers is that they are present in biofluids such as serum, plasma, urine, seminal fluid, CSF, saliva, tears and breast milk. This makes exosome-based diagnostics practical, because of their ease of use, speed of detection, and minimally invasive nature. Exosomes can also act as prognostic indicators and predictors of a patient’s response to a particular treatment course.
Another emerging application of exosomes is their use as therapeutics. For example, if a patient has a disease caused by a missing or defective protein or microRNA, the patient’s exosomes can be isolated, modified with the appropriate siRNA or protein, and injected back into the patient for treatment. There are also many approaches being researched for creating drug-loaded exosomes. Additionally, exosomes from stem cells appear to exert powerful effects. For example, MSC-derived exosomes have the capacity to suppress inflammation, prevent scar tissue formation, and mediate a healthy immune response.
For these reasons, exosomes have gone from being overlooked to rapidly gaining momentum as a novel strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering whole cells to patients. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to give credit to exosomes for a range of promising traits. Fifteen years ago in 2006, there was a paltry 76 articles published about exosomes on PubMed.gov. Today, there are more than 17,850 articles published about exosomes on PubMed.gov, of which the vast majority were released in the past five years.
When exosome publications are analyzed, U.S. authors have published approximately 40% of the articles and China comes in second place. When the term “exosome” is searched in the scientific literature, Dr. Susanne Gabrielsson from the Karolinska Institutet in Sweden is the leading author. When the term “extracellular vesicles” is searched, Unicyte AG, a regenerative medicine unit of Fresenius Medical Care, takes the lead. Headquartered in Switzerland, the company has published more than 100 papers on exosomes and extracellular vesicles in combination with Professor Giovanni Camussi.
Exosome Market Forces
Exosome-related technologies have been developing rapidly over the past few years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine and regenerative medicine. In particular, cancer derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection. When it comes to stem cell exosomes specifically, mesenchymal stem cell (MSC) derived exosomes are best represented within the scientific literature and global patent activity.
To characterize this rapidly forming marketplace, BioInformant has released a 358-page global market report that explores growing demand for exosome therapeutics, diagnostics, research tools, and manufacturing technologies. The report reveals trend rate data for exosome patents, grants, scientific publications, and clinical trials. It highlights information about exosome industry partnerships, merger and acquisition (M&A) activity, and financing events. Importantly, it presents market size determinations by segment with forecasts through 2028.
Today in 2021, the exosome industry is witnessing:
- A surging number of scientific papers investigating exosomes and their applications
- Rising numbers of clinicals trials investigating exosome therapeutics and diagnostics
- An insatiable appetite among investors for exosome technology
- An increasingly competitive IP environment
- A diverse range of co-development partnerships
- Proliferating numbers of exosome competitors across all major life science markets worldwide
This 358-page global strategic report about the exosome industry reveals:
- The pipeline for exosome cell therapeutics in 2021
- Clinical trial activity by type, region, phase, and sponsor
- Exosome industry events, including M&A activity, financing events, and IPOs
- Strategic partnerships and co-development agreements
- Competitors composing the global marketplace, including core technologies and products under development
- Market size determinations by segment with forecasts through 2028
- Exosome industry trends, competitive opportunities, and future directions for the global market
- And so much more
Claim this global strategic report to:
- Get educated about the rapidly evolving exosome market
- Identify opportunities for exosome product development
- Reveal the identities of all known competitors developing exosome research products, diagnostics, therapeutics, and manufacturing technologies
- Determine company strategy or purse external funding from investors
- Make smarter decisions, faster
With an online readership of nearly one million viewers per year, BioInformant is a U.S. market research firm with nearly 15 years of experience. As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. Headquartered in Washington, DC, BioInformant is strategically positioned to be near the National Institutes of Health (NIH), the U.S. FDA, the Maryland Biotech Corridor, and policy makers on Capital Hill.
The content within this report was compiled using a diverse range of sources, as described in this Research Methodology.
View Table of Contents: The Global Exosome Market – Market Size, Forecast, Trials and Trends, 2021
Remember, all BioInformant products come with a Greater Than 100% Money Back Guarantee. If the strategies and tools aren’t helpful to you – we’ll cheerfully refund your money, and you can keep the product.
Have questions? Email us at [email protected] to get a rapid reply. Checkout below to get immediate access to this report as an electronic (PDF) file, with printing rights allowed.